Oryzon Genomics SA (ES:ORY) has released an update.
Oryzon Genomics S.A., a leader in epigenetics-based personalized medicine, has successfully passed all resolutions at its 2024 Annual General Shareholders’ Meeting, with notable approval for a capital increase up to 100 million euros. Shareholders also endorsed the annual report, management efforts, auditor election, and Board of Directors’ remuneration for 2023.
For further insights into ES:ORY stock, check out TipRanks’ Stock Analysis page.